Related Experiment Videos
Reduced C4 in HLA-B8 positive patients with Graves' disease
Insights
Serum C4 levels were lower in Graves' disease patients, particularly those with HLA-B8. This finding suggests a potential role for reduced complement component 4 in Graves' disease pathogenesis.
Area of Science:
- Immunology
- Endocrinology
- Genetics
Background:
- Graves' disease is an autoimmune disorder affecting the thyroid.
- The role of complement system components, like C3 and C4, in Graves' disease pathogenesis is not fully understood.
- HLA-B8 is a genetic marker associated with an increased risk of Graves' disease.
Purpose of the Study:
- To investigate serum concentrations of complement components C3 and C4 in patients with Graves' disease.
- To explore potential correlations between C3/C4 levels, HLA-B8 status, and Graves' disease.
Main Methods:
- Serum samples were collected from 49 patients with Graves' disease and 50 healthy controls.
- Serum concentrations of C3 and C4 were measured using standard laboratory assays.
- Patients were genotyped for HLA-B8 status.
Main Results:
- No significant differences in overall C3 or C4 levels were found between Graves' disease patients and controls.
- However, C4 concentrations were significantly lower in HLA-B8 positive Graves' disease patients compared to HLA-B8 negative patients (p < 0.05).
- This reduction in C4 was more pronounced in treated, euthyroid HLA-B8 positive patients (p < 0.02).
Conclusions:
- Reduced serum C4 concentration may be associated with Graves' disease, particularly in HLA-B8 positive individuals.
- These findings suggest a potential role for the complement system, specifically C4, in the pathogenesis of Graves' disease.
- Further research is warranted to elucidate the precise mechanisms involved.
Abstract:
We studied the serum concentration of C3 and C4 in 50 controls and 49 patients suffering from Graves' disease. No difference was observed in C3 or C4 levels between the patient and control groups as a whole nor when HLA-B8 positive or negative patients were compared with the corresponding control group. Nevertheless, C4 concentrations were significantly lower in HLA-B8 patients with Graves' disease compared to antigen negative patients (30.6 +/- 10.3 vs. 36.9 +/- 10.2 mg/100 ml, p less than 0.05). This difference in C4 levels was even more pronounced when only treated euthyroid patients were compared (27.2 +/- 6.4 mg/100 ml, for B8 positive vs. 35.9 +/- 10.7 mg/100 ml for B8 negative patients, p less than 0.02). These results suggest that reduction in C4 concentration may play a role in the pathogenesis of Graves' disease.